Fairvalue-Calculator Fairvalue-Calculator
EN DE

Sera Prognostics, Inc (SERA) Fair Value & Analysis

Healthcare · US · Market cap $72.2M

Price$1.80
Fair Value$0.3700
Upside-79.4%
Quality95/100
Evidence: Low Range $0.2500 – $0.4700

Fair value as of: Jun 25, 2026

Analysis

Sera Prognostics, Inc (SERA) currently trades at $1.80, while our model-based Fair Value estimate is $0.3700 — implying the stock looks roughly 79.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -23% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -81% Edwards Lifesciences Corporation (EW) -53% Siemens Healthineers AG (SEMHF) +19%

Frequently asked questions

Is Sera Prognostics, Inc (SERA) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $0.3700 versus a price of $1.80 — about −79% (overvalued). Model-based estimate, not financial advice.
What is the fair value of SERA?
Our 21-model fair value for Sera Prognostics, Inc is $0.3700 (as of Jun 25, 2026), built from audited fundamentals. The current price is $1.80.
What is the quality score of SERA?
Sera Prognostics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.